Although achieving therapeutic levels with intravitreal formulations is challenging due to dilution in the vitreous and variable retinal penetration dictated by molecular characteristics, all of the complement inhibitors currently in late-stage clinical trials for AMD are being administered intravitreally, including pegcetacoplan, an anti-C3 agent, and avacincaptad pegol, an anti-C5 agent. Here, C5 is linked to age-related macular degeneration.